This study is for people with endometrial cancer (EC) who have already tried two types of treatments: platinum-based therapy (a kind of chemotherapy) and immunotherapy (a treatment that boosts the immune system to fight cancer). Researchers want to see if a new drug, called MK-2870 sacituzumab tirumotecan, can help patients live longer and stop the cancer from getting worse compared to regular chemotherapy.

Eligibility: You can join if you have endometrial carcinoma or carcinosarcoma (types of cancer) that can be seen on scans. You must have had platinum-based chemotherapy and immunotherapy before. You cannot join if you have certain other types of cancer or health issues like severe eye problems or bowel disease. There are also limits on how many other treatments you've had.

• Participation: You'll receive either the new drug or chemotherapy.
• Time: The study will monitor your health and cancer progress over time.
• Considerations: There are eligibility criteria based on previous treatments and health conditions.

This study hopes to find a better treatment option for endometrial cancer patients.